News | Breast Imaging | January 29, 2020

University of Chicago Offers Mammosphere from Life Image to Support WISDOM Study Participants, Improve Research

Top academic medical center to leverage leading breast health data tool to improve breast screening protocols for groundbreaking study

Mammogram showing dense breast tissue

January 29, 2020 — Life Image announced that it will provide Mammosphere, a breast health data access tool, to the University of Chicago Medicine to support recruitment for a pioneering research effort.

This leading academic medical center, which performed more than 14,000 outpatient mammography exams in 2018, serves a unique and diverse patient base across the Chicagoland area. It is the first Midwest expansion partner site for the WISDOM Study, a large-scale clinical trial aimed at developing optimal guidelines for breast cancer screening.

Mammosphere, a HIPAA-compliant, digital tool that allows women to securely request, store, and share breast images and reports with providers, will allow University of Chicago Medicine to bolster the accessibility and availability of prior breast health records. It creates a longitudinal view of the individual patient’s breast history to track changes over time, providing the historical medical records that are integral to support the WISDOM Study.

Life Image is also providing UChicago Medicine with the ability to streamline access to picture archiving communication systems (PACS) and electronic health record (EHR) systems in order to modernize processes for sharing information with patients. As WISDOM participation in the Chicago area increases, UChicago Medicine will be able to more effectively manage a high volume of requests from participants to receive and share breast health records without delay at its locations and affiliate sites. 

The WISDOM Study aims to recruit 100,000 women in order to improve breast cancer screening guidelines. The study follows participants over time to determine whether a personalized, risk-based screening protocol can improve clinical outcomes when compared to the current, one-size-fits-all approach to screening.

“As a partner of the WISDOM Study, we are committed to supporting the research that will end the confusion for all women around screening guidelines based on patients’ unique risk factors,” said Deepa Sheth, M.D., assistant professor of radiology, UChicago Medicine. “In the era of precision medicine, we have the opportunity to find the correct breast health screening protocol for an individual based on their risk, and by engaging our diverse community we can be certain the data and results are ethnically universal and applicable to any and all women.”

Mammosphere was developed to support women throughout their entire breast health journey, including contributing to scientific research. By offering patients this digital tool, patients in the WISDOM Study will have additional tools to support their long-term commitment to the research.

“It is an honor to work with one of the country’s top academic medical centers to provide the digital platform that enables this groundbreaking study,” said Matthew Michela, CEO, Life Image. “Life Image, UChicago Medicine, and the WISDOM Study are committed to working in tandem to answer critical questions to improve women’s breast health and the patient experience.”

WISDOM is a five-year longitudinal study that compares two different approaches to breast cancer screening – personalized screening versus annual screening. The personalized screening approach will take multiple risk factors into consideration, including genetic markers, to determine the most effective screening frequency and modality for an individual. Over time, the WISDOM Study hopes to discover which risk factors are most important, allowing regulators and providers to improve our screening recommendations accordingly. To learn more about the WISDOM Study, or sign up: www.wisdomstudy.org

Related Content

Simulation finds starting at age 30 with MRI and mammography to be the preferred strategy; starting at 25 prevented marginally more deaths, but with more testing and emotional stress

Getty Images

News | Breast Imaging | July 09, 2020
July 9, 2020 — Chest radiation is used to treat children with Hodgkin and non-Hodgkin lymphoma as well as lung metast
Hologic, Inc. announced he U.S. launch of the SuperSonic MACH 40 ultrasound system, expanding the company’s suite of ultrasound technologies with its first premium, cart-based system.
News | Breast Imaging | July 08, 2020
July 8, 2020 — Hologic, Inc. announced he U.S.
In new QuickPoLL survey on imaging during the pandemic, responses were tallied from around 170 radiology administrators and business managers, who are part of an imagePRO panel created by The MarkeTech Group (TMTG), regarding the effects of COVID-19 on their business. TMTG is a research firm specializing in the medical device, healthcare and pharmaceutical industries.
Feature | Coronavirus (COVID-19) | June 30, 2020 | By Melinda Taschetta-Millane
VolparaEnterprise data analysis shows mammography screening volumes are quickly increasing
News | Mammography | June 09, 2020
June 9, 2020 — More than 75 percent of hospitals and imaging centers that perform mammography across the United State
Developed by medical AI company Lunit, Software detects breast cancer with 97% accuracy; Study in Lancet Digital Health shows that Lunit INSIGHT MMG-aided radiologists showed an increase in sensitivity

Lunit INSIGHT MMG

News | Artificial Intelligence | June 02, 2020
June 2, 2020 — Lunit announced that its artificia...
AI has the potential to help radiologists improve the efficiency and effectiveness of breast cancer imaging

Getty Images

Feature | Breast Imaging | May 28, 2020 | By January Lopez, M.D.
Headlines around the world the past several months declared that...
a Schematic of the system. The entire solid tumour is illuminated from four sides by a four-arm fibre bundle. A cylindrically focused linear array is designed to detect optoacoustic signals from the tumour. In vivo imaging is performed in conical scanning geometry by controlling the rotation and translation stages. The sensing part of the transducer array and the tumour are submerged in water to provide acoustic coupling. b Maximum intensity projections of the optoacoustic reconstruction of a phantom of pol

a Schematic of the system. The entire solid tumour is illuminated from four sides by a four-arm fibre bundle. A cylindrically focused linear array is designed to detect optoacoustic signals from the tumour. In vivo imaging is performed in conical scanning geometry by controlling the rotation and translation stages. The sensing part of the transducer array and the tumour are submerged in water to provide acoustic coupling. b Maximum intensity projections of the optoacoustic reconstruction of a phantom of polyethylene microspheres (diameter, 20 μm) dispersed in agar. The inset shows a zoomed-in view of the region boxed with a yellow dashed line. In addition, the yellow boxes are signal profiles along the xy and z axes across the microsphere centre, as well as the corresponding full width at half-maximum values. c Normalized absorption spectra of Hb, HbO2 and gold nanoparticles (AuNPs). The spectrum for the AuNPs was obtained using a USB4000 spectrometer (Ocean Optics, Dunedin, FL, USA), while the spectra for Hb and HbO2 were taken from http://omlc.org/spectra/haemoglobin/index.html. The vertical dashed lines indicate the five wavelengths used to stimulate the three absorbers: 710, 750, 780, 810 and 850 nm. Optoacoustic signals were filtered into a low-frequency band (red) and high-frequency band (green), which were used to reconstruct separate images.

News | Breast Imaging | May 26, 2020
May 26, 2020 — Breast cancer is the most common cancer in women.
Phone call and linkage-to-care-based intervention increases mammography uptake among primary care patients at an urban safety-net hospital

Getty Images

News | Mammography | May 22, 2020
May 22, 2020 — Telephone outreach coupled with scheduling assistance significantly increased...
The Breast Imaging and Reporting System (BI-RADS) was established by the American College of Radiology to help classify findings on mammography. Findings are classified based on the risk of breast cancer, with a BI-RADS 2 lesion being benign, or not cancerous, and BI-RADS 6 representing a lesion that is biopsy-proven to be malignant.

Getty Images

News | Breast Imaging | May 19, 2020
May 19, 2020 — Women with mammographically detected breast lesions that are probably benign should have follow-up sur